title: Magnesium hydroxide in ibuprofen tablet reduces the gastric mucosal tolerability of ibuprofen.
abstract: OBJECTIVE
  The study was designed to compare the gastrointestinal tolerability of a magnesium hydroxide-containing ibuprofen tablet (buffered ibuprofen) and the conventional ibuprofen tablet in healthy volunteers.
  
  
  BACKGROUND
  Magnesium hydroxide has been shown to increase the rate of absorption of ibuprofen.
  
  
  METHODS
  A double blind, randomized, 2-period crossover study design was used. Twenty healthy men ingested 800 mg ibuprofen 3 times daily either in conventional tablets (2 doses of 400 mg) or in tablets containing magnesium hydroxide (2 doses of 400 mg ibuprofen and 200 mg magnesium hydroxide). On the 5th day only the morning dose was administered. Endoscopy was performed at baseline and on the 5th day in both treatments 2 hours after the last dose, and gastric pH was determined. In addition, plasma concentrations of ibuprofen were determined up to 90 minutes.
  
  
  RESULTS
  The magnesium hydroxide-containing formulation increased the number of subjects evincing erosions in gastric corpus and antrum. In the gastric corpus 2 and 7 volunteers had erosions after conventional and buffered ibuprofen, respectively (P = 0.08). In the gastric antrum 5 and 13 volunteers showed erosions after conventional and buffered ibuprofen, respectively (P = 0.02). There was a trend toward faster absorption of ibuprofen when given together with magnesium hydroxide. The difference was not however statistically significant.
  
  
  CONCLUSIONS
  Prolonged use of magnesium hydroxide together with high doses of ibuprofen should be avoided, because the combination may incur a higher risk of gastrointestinal irritation.
authors.affiliation: Leiras Oy, Helsinki, Finland. jukka.maenpaa@santen.fi
authors.forename: Jukka
authors.initials: J
authors.lastname: Mäenpää
authors.forename: Anneli
authors.initials: A
authors.lastname: Tarpila
authors.forename: Taneli
authors.initials: T
authors.lastname: Jouhikainen
authors.forename: Harri
authors.initials: H
authors.lastname: Ikävalko
authors.forename: Eliisa
authors.initials: E
authors.lastname: Löyttyniemi
authors.forename: Kristiina
authors.initials: K
authors.lastname: Perttunen
authors.forename: Pertti J
authors.initials: PJ
authors.lastname: Neuvonen
authors.forename: Simo
authors.initials: S
authors.lastname: Tarpila
mesh_terms: D000136:Acid-Base Equilibrium / Q000187:drug effects; D000328:Adult; D000863:Antacids / Q000494:pharmacology*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics / Q000494:pharmacology*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004338:Drug Combinations; D004347:Drug Interactions; D004386:Duodenum / Q000187:drug effects; D020776:Endoscopes, Gastrointestinal; D005753:Gastric Mucosa / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007052:Ibuprofen / Q000493:pharmacokinetics / Q000494:pharmacology*; D008276:Magnesium Hydroxide / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged
chemical_list: D000863:Antacids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; D008276:Magnesium Hydroxide; D007052:Ibuprofen